Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Tonlamarsen · ION-904

Oligonucleotide (Antisense oligonucleotide) · developed by Kardigan

Phase 2 Most advanced trial

KARD Developer

1 Registered trials

What is Tonlamarsen?

Tonlamarsen is an investigational oligonucleotide studied in Hypertension, Acute Severe Hypertension, Hypertensive Emergency.

At a glance

Also known as: ION-904
Drug type: Oligonucleotide (Antisense oligonucleotide)
Therapy area: Cardiovascular
Developer: Kardigan, Inc. (KARD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: W6YJ85G6YG

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07511361	Phase 2	Hypertension	Recruiting	KARD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Severe HypertensionHypertensionHypertensive EmergencyHypertensive Urgency

More from Kardigan

Ataciguat Phase 2/3 Danicamtiv Phase 3

Sources

ClinicalTrials.gov NCT07511361

Updated Oct 3, 2026. Something wrong or missing? Report it on the KARD page.

Follow KARD, the company behind Tonlamarsen

See KARD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KARD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z